-
Misery for Maresca as Man City make dismal start to life after Guardiola
-
Spanish soldier dies in Aragon wildfire: regional leader
-
Strikes kill 19 in Russia and Ukraine
-
Belgium's Pocognoli appointed new Scotland manager
-
Lula and Bolsonaro court women voters as Brazil election campaign kicks off
-
Marchand storms to second gold of European championships
-
Belgium races to tame huge wildfire creeping towards Germany
-
Kushner meets with Hamas in push to revive Gaza plan
-
Two dead, hundreds evacuated from fires on island near Athens
-
Villarreal battle back to earn draw at promoted Racing
-
Real Madrid crush Schalke in friendly as Diomande debuts
-
Odegaard says Arsenal 'want to win everything' after Community Shield success
-
Calls for UK inquiry into 'hounding' of ex-Cambridge academic
-
Arsenal rout Man City in Community Shield masterclass
-
Strikes kill 16 in Russia and Ukraine
-
Southampton mocked over Spygate during Watford defeat
-
Marchand tries for European swim gold in unfamiliar event
-
Hamas expects meeting with Kushner as US pushes Gaza plan
-
India's Padikkal steals the show with 167 in first Sri Lanka Test
-
Farmers, helicopters help battle record Belgian wildfire
-
Hollywood duo underline Premier League ambition for Wrexham
-
Air support kicks in as record Belgian wildfire jumps in size
-
India's Padikkal makes 167 in first Sri Lanka Test
-
Firefighters battle second day of blaze on Greek island
-
Hurricane Lala pulls away from Hawaii's Big Island
-
Strikes kill 12 in Russia and Ukraine
-
Petros, Vainio set new championship records to win Euro marathons
-
India's Sindhu backs monkey measures as badminton worlds set to open
-
Hurricane Lala brushes past Hawaii's Big Island, bringing heavy rain
-
Mass drone attack on Moscow as Russian strikes kill three in Ukraine
-
'Something we dreamed of': Bangladesh celebrates historic cricket win
-
Djokovic feels the heat in Cincinnati defeat, Zverev wins all-nighter
-
Rain holds up India on day two of Sri Lanka Test
-
Pallister stuns Ledecky in Pan Pacs 800m free as two world records carry Douglass to gold
-
The Ukrainian social media channels tracking Russian missiles
-
Rampant Bangladesh make history with first-ever Test win in Australia
-
Disney offers fans an escapist bubble at D23 event
-
UK's media-savvy PM Burnham shifts messaging to TikTok, podcasts
-
Thousands await aid after deadly Indonesian quake
-
Gay badminton star Gilmour urges progress on LGBTQ rights in Asia
-
Chinese ship sets off for Europe through Arctic, halving travel time
-
Pallister takes down Ledecky in Pan Pacs 800m freestyle
-
Bangladesh on verge of historic win in Australia as Mehidy takes five
-
Douglass breaks 50m free world record again to claim Pan Pacs gold
-
Messi sees penalty saved as Nashville routs Inter Miami in MLS
-
As Opel turns to Chinese partners, its hometown frets about the future
-
Heat is on as German winegrowers struggle to protect vines
-
Mehidy takes three as Bangladesh close on historic win in Australia
-
Hope fades for finding survivors of Colombia quake as rescued woman dies
-
Hope fades for finding surivivors of Colombia quake as rescued woman dies
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Norris--AMWN